Investigating new treatments for triple-negative breast cancer
Mechanistic studies of hirsutinolides and azetidine-based small molecule inhibitors of STAT3
['FUNDING_R01'] · CEDARS-SINAI MEDICAL CENTER · NIH-11061191
This study is exploring new ways to treat triple-negative breast cancer by targeting how the cancer cells use sugar and handle stress, with the hope of finding better treatment options that could help patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CEDARS-SINAI MEDICAL CENTER (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-11061191 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new therapeutic strategies for triple-negative breast cancer (TNBC), a type of cancer that often does not respond well to standard chemotherapy. The approach involves targeting specific cellular mechanisms that TNBC cells rely on for survival, particularly those related to glucose metabolism and oxidative stress. By using small molecule inhibitors that affect these pathways, the research aims to induce cell death in cancer cells and inhibit tumor growth. Patients may benefit from potential new treatment options that could improve outcomes for this challenging cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer or those who have already responded well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach may lead to significant advancements.
Where this research is happening
LOS ANGELES, UNITED STATES
- CEDARS-SINAI MEDICAL CENTER — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TURKSON, JAMES K — CEDARS-SINAI MEDICAL CENTER
- Study coordinator: TURKSON, JAMES K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.